New Treatment for Certain Bacterial Pneumonia Receives FDA Approval – APhA submits compounding comments to FDA. – (866) 348-2889.
Officials with the FDA have approved a new indication for ceftolozane and tazobactam combination (Zerbaxa, Merck) drug. The new approval indicates the medication for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients age 18 years and older.
Ceftolozane and tazobactam was initially approved by the FDA in 2014 for treating complicated intra-abdominal infections and for complicated urinary tract infections.